Petra Nytrova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Longitudinal assessment of sNfL and sGFAP in severe NMOSD treated with allogeneic stem cell transplantation.

Longitudinal assessment of sNfL and sGFAP in severe NMOSD treated with allogeneic stem cell transplantation.

Journal: Frontiers in immunology

Published: March 17, 2026

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology

Published: March 05, 2026

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.

Journal: Journal of neurology

Published: January 06, 2025

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.

Journal: Neurology

Published: November 19, 2024

SARS-CoV-2 Is Linked to Brain Volume Loss in Multiple Sclerosis.

SARS-CoV-2 Is Linked to Brain Volume Loss in Multiple Sclerosis.

Journal: Annals of clinical and translational neurology

Published: September 26, 2024

Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity.

Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity.

Journal: Clinical immunology (Orlando, Fla.)

Published: May 22, 2024

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 21, 2024

Abnormal Cerebrospinal Fluid Cytology in Functional Movement Disorders.

Abnormal Cerebrospinal Fluid Cytology in Functional Movement Disorders.

Journal: Psychosomatic medicine

Published: April 04, 2024

Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.

Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.

Journal: Multiple sclerosis and related disorders

Published: January 07, 2024

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.

Journal: PloS one

Published: December 22, 2023

Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.

Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.

Journal: Clinical and experimental immunology

Published: October 05, 2023

Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity.

Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity.

Journal: iScience

Published: September 19, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026